Topiramate in substance-related and addictive disorders;Le topiramate a-t-il un intérêt en addictologie?

Presse Medicale

Volumn 43, Issue 9, 2014, Pages 892-901

  Cohen, Johan ^a   Dervaux, Alain ^a   Laqueille, Xavier ^a  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BENZODIAZEPINE; CANNABIS; CARBON MONOXIDE; COCAINE; DIAMORPHINE; NICOTINE; OPIATE; TOPIRAMATE; DRUG DERIVATIVE; FRUCTOSE; NEUROPROTECTIVE AGENT;

ADDICTION; ALCOHOLISM; ARTICLE; BENZODIAZEPINE DEPENDENCE; BINGE EATING DISORDER; BODY WEIGHT; BULIMIA; CANNABIS ADDICTION; CLINICAL EFFECTIVENESS; COCAINE DEPENDENCE; DATA ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; GAMBLING; HEROIN DEPENDENCE; HUMAN; META ANALYSIS (TOPIC); METHAMPHETAMINE DEPENDENCE; OPIATE ADDICTION; OUTCOME ASSESSMENT; QUALITY CONTROL; SUBSTANCE ABUSE; TOBACCO; TOBACCO DEPENDENCE; TREND STUDY; CLINICAL TRIAL (TOPIC); EATING DISORDER; REVIEW;

BEHAVIOR, ADDICTIVE; CLINICAL TRIALS AS TOPIC; EATING DISORDERS; FRUCTOSE; GAMBLING; HUMANS; NEUROPROTECTIVE AGENTS; SUBSTANCE-RELATED DISORDERS;

EID: 84908261702     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2014.02.030     Document Type: Article

References (69)

1. Hasin D.S., Stinson F.S., Ogburn E., Grant B.F. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch General Psychiatry 2007, 64:830-842.
2. Wittchen H.U., Jacobi F., Rehm J., Gustavsson A., Svensson M., Jonsson B., et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuro Psychopharmacol 2011, 21:655-679.
3. WHO Global health risks: mortality and burden of disease attributable to selected major risks 2009, [Accès au site le 11/06/2014]. http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf.
4. van den Brink W. Evidence-based pharmacological treatment of substance use disorders and pathological gambling. Curr Drug Abuse Rev 2012, 5:3-31.
5. FDA FDA approves weight-management drug Qsymia 2012, [Accès au site le 11/06/2014]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312468.htm.
6. Johnson B.A., Ait-Daoud N. Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des 2010, 16:2103-2112.
7. Guardia D., Rolland B., Deheul S., Danel T., Bordet R., Cottencin O. Supervised off-label prescribing of topiramate for binge eating disorder within the system CAMTEA. Therapie 2012, 67:480-481.
8. Shinn A.K., Greenfield S.F. Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psychiatry 2010, 71:634-648.
9. Florez G., Saiz P.A., Garcia-Portilla P., Alvarez S., Nogueiras L., Bobes J. Topiramate for the treatment of alcohol dependence: comparison with naltrexone. Eur Addict Res 2011, 17:29-36.
10. Paparrigopoulos T., Tzavellas E., Karaiskos D., Kourlaba G., Liappas I. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC Psychiatry 2011, 11:41.
11. Rubio G., Martinez-Gras I., Manzanares J. Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence. J Clin Psychopharmacol 2009, 29:584-589.
12. Mariani J.J., Pavlicova M., Bisaga A., Nunes E.V., Brooks D.J., Levin F.R. Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. Biol Psychiatry 2012, 72:950-956.
13. Johnson B.A., Ait-Daoud N., Wang X.Q., Penberthy J.K., Javors M.A., Seneviratne C., et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry 2013, 70:1338-1346.
14. Kampman K.M., Pettinati H.M., Lynch K.G., Spratt K., Wierzbicki M.R., O'Brien C.P. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend 2013, 133:94-99.
15. Elkashef A., Kahn R., Yu E., Iturriaga E., Li S.H., Anderson A., et al. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction 2012, 107:1297-1306.
16. Ma J.Z., Johnson B.A., Yu E., Weiss D., McSherry F., Saadvandi J., et al. Fine-grain analysis of the treatment effect of topiramate on methamphetamine addiction with latent variable analysis. Drug Alcohol Depend 2013, 130:45-51.
17. Guardia D., Rolland B., Karila L., Cottencin O. GABAergic and glutamatergic modulation in binge eating: therapeutic approach. Curr Pharm Des 2011, 17:1396-1409.
18. Johnson B.A., Ait-Daoud N., Bowden C.L., DiClemente C.C., Roache J.D., Lawson K., et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003, 361:1677-1685.
19. Johnson B.A., Ait-Daoud N., Akhtar F.Z., Ma J.Z. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry 2004, 61:905-912.
20. Johnson B.A., Rosenthal N., Capece J.A., Wiegand F., Mao L., Beyers K., et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2001, 298:1641-1651.
21. Johnson B.A., Rosenthal N., Capece J.A., Wiegand F., Mao L., Beyers K., et al. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med 2008, 168:1188-1199.
22. Baltieri D.A., Daro F.R., Ribeiro P.L., de Andrade A.G. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 2008, 103:2035-2044.
23. Arbaizar B., Diersen-Sotos T., Gomez-Acebo I., Llorca J. Topiramate in the treatment of alcohol dependence: a meta-analysis. Actas Esp Psiquiatr 2010, 38:8-12.
24. Florez G., Garcia-Portilla P., Alvarez S., Saiz P.A., Nogueiras L., Bobes J. Using topiramate or naltrexone for the treatment of alcohol-dependent patients. Alcohol Clin Exp Res 2008, 32:1251-1259.
25. De Sousa A.A., De Sousa J., Kapoor H. An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. J Subst Abuse Treat 2008, 34:460-463.
26. Anthenelli R.M., Blom T.J., McElroy S.L., Keck P.E. Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation. Addiction 2008, 103:687-694.
27. Baltieri D.A., Daro F.R., Ribeiro P.L., Andrade A.G. Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients. Drug Alcohol Depend 2009, 105:33-41.
28. Johnson B.A., Ait-Daoud N., Akhtar F.Z., Javors M.A. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Intern Med 2005, 165:1600-1605.
29. Kampman K.M., Pettinati H., Lynch K.G., Dackis C., Sparkman T., Weigley C., et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004, 75:233-240.
30. Hedges D.W., Reimherr F.W., Hoopes S.P., Rosenthal N.R., Kamin M., Karim R., et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry 2003, 64:1449-1454.
31. Hoopes S.P., Reimherr F.W., Hedges D.W., Rosenthal N.R., Kamin M., Karim R., et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry 2003, 64:1335-1341.
32. Nickel C., Tritt K., Muehlbacher M., Pedrosa Gil F., Mitterlehner F.O., Kaplan P., et al. Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial. Int J Eat Disord 2005, 38:295-300.
33. McElroy S.L., Arnold L.M., Shapira N.A., Keck P.E., Rosenthal N.R., Karim M.R., et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003, 160:255-261.
34. McElroy S.L., Hudson J.I., Capece J.A., Beyers K., Fisher A.C., Rosenthal N.R., et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 2007, 61:1039-1048.
35. Claudino A.M., de Oliveira I.R., Appolinario J.C., Cordas T.A., Duchesne M., Sichieri R., et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry 2007, 68:1324-1332.
36. Berlin H.A., Braun A., Simeon D., Koran L.M., Potenza M.N., McElroy S.L., et al. A double-blind, placebo-controlled trial of topiramate for pathological gambling. World J Biol Psychiatry 2013, 14:121-128.
37. Dannon P.N., Lowengrub K., Gonopolski Y., Musin E., Kotler M. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol 2005, 28:6-10.
38. ANSM Mise en garde sur le détournement de l'usage d'Epitomax® à visée amaigrissante en dehors des indications autorisées 2011, [Accès au site le 11/06/2014]. http://www.ansm.sante.fr/Infos-de-securite/Points-d-information/Mise-en-garde-sur-le-detournement-de-l-usage-d-Epitomax-R-a-visee-amaigrissante-en-dehors-des-indications-autorisees-Point-d-information/(language)/fre-FR.
39. Etminan M., Maberley D., Mikelberg F.S. Use of topiramate and risk of glaucoma: a case-control study. Am J Ophthalmol 2012, 153:827-830.
40. ClinicalTrials.gov. Identifier: . Topiramate for hospitalized patients with alcoholism: a 12-week study (THoPA-O). ; 2010. [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/ct2/show/NCT01135602.
41. ClinicalTrials.gov Identifier: . Efficacy of topiramate for hospitalized patients with alcoholism (ETHoPA-R). ; 2010 [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/ct2/show/NCT01145677.
42. ClinicalTrials.gov Identifier: . Aripiprazole and topiramate on free-choice alcohol use. ; 2009 [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/show/NCT00884884.
43. ClinicalTrials.gov Identifier: . Combining medications for the treatment of alcohol dependence: an inpatient preliminary study. ; 2012 [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/ct2/show/NCT00769158.
44. ClinicalTrials.gov Identifier: . Alcohol dependency study: combining medication treatment for alcoholism. ; 2013 [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/ct2/show/NCT00006205%3Fterm=Addiction%26recr=Open%26lup_s=01%20%2F15%20%2F2013%26lup_d=360.
45. ClinicalTrials.gov Identifier: . Interdisciplinary study of two novel anticonvulsants in alcoholism. ; 2013 [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/ct2/show/NCT00862563.
46. ClinicalTrials.gov Identifier: . Topiramate for alcohol use in posttraumatic stress disorder. ; 2012 [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/show/NCT01408641.
47. ClinicalTrials.gov Identifier: . Topiramate treatment of alcohol use disorders in veterans with post traumatic stress disorder (PTSD): a pilot controlled trial of augmentation therapy (TAP). ; 2014 [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/ct2/show/NCT01087736%3Frecr=Open%26state3=NA%3AUS%3ACA%26lup_s=02%20%2F15%20%2F2010%26lup_d=30.
48. ClinicalTrials.gov Identifier: . A controlled trial of topiramate treatment for alcohol dependence in veterans with PTSD (TAP2). ; 2014 [Accès au site le 11/06/2014]. http://clinicaltrials.gov/show/NCT01749215.
49. ClinicalTrials.gov Identifier: . Adjunctive topiramate for treatment of alcohol dependence in patients with bipolar disorder. ; 2012 [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/ct2/show/NCT00572117.
50. ClinicalTrials.gov Identifier: . Efficacy and tolerability of topiramate in treatment of bipolar mania and alcohol use in adolescents and young adults. ; 2013 [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/ct2/show/NCT00550394.
51. ClinicalTrials.gov Identifier: . Topiramate for the treatment of alcohol dependent binge-eating disordered individuals. ; 2012 [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/show/NCT00300742.
52. ClinicalTrials.gov Identifier: . Topiramate to reduce heavy drinking in hiv-positive heavy drinkers. ; 2013 [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/show/NCT01764685.
53. ClinicalTrials.gov Identifier: . Topiramate Alone and in combination with the nicotine patch for smoking cessation: a pilot study. ; 2012 [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/ct2/show/NCT00755716.
54. ClinicalTrials.gov Identifier: . A pilot study of the neural correlates of treatment effect on nicotine craving. ; 2006 [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/ct2/show/NCT00208858.
55. ClinicalTrials.gov Identifier: . Multicenter trial of combined pharmacotherapy to treat cocaine dependence (TACT2). ; 2014 [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/ct2/show/NCT01811940.
56. ClinicalTrials.gov Identifier: . Novel pharmacotherapy for dual dependence. ; 2013 [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/show/NCT00448825.
57. ClinicalTrials.gov Identifier: . New treatment for alcohol and nicotine dependence. ; 2014 [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/show/NCT01182766.
58. ClinicalTrials.gov Identifier: . Topiramate to aid smoking cessation in alcohol dependent men. ; 2014 [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/show/NCT00802412.
59. ClinicalTrials.gov Identifier: . Biobehavioral effects of topiramate on cannabis-related outcomes in adolescents. ; 2012 [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/ct2/show/NCT01110434.
60. ClinicalTrials.gov Identifier: . Efficacy study of quetiapine plus topiramate for reducing cannabis consumption and bipolar mania. ; 2014 [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/show/NCT00393978.
61. ClinicalTrials.gov Identifier: . Topiramate for binge eating disorder among adolescents. ; 2014 [Accès au site le 11/06/2014]. http://www.clinicaltrials.gov/ct2/show/NCT00768677.
62. Leo R.J., Baer D. Delirium associated with baclofen withdrawal: a review of common presentations and management strategies. Psychosomatics 2005, 46:503-507.
63. O'Rourke F., Steinberg R., Ghosh P., Khan S. Withdrawal of baclofen may cause acute confusion in elderly patients. BMJ 2001, 323:870.
64. Soufia M., Plaze M., Gueguen B., Demigneux G., Olie J.P., Gaillard R. Behavioral disinhibition with baclofen. J Clin Psychopharmacol 2010, 30:759-760.
65. Skolnick P., Volkow N.D. Addiction therapeutics: obstacles and opportunities. Biol Psychiatry 2012, 72:890-891.
66. Luquiens A., Reynaud M., Aubin H.J. Is controlled drinking an acceptable goal in the treatment of alcohol dependence? A survey of French alcohol specialists. Alcohol 2011, 46:586-591.
67. Rehm J., Zatonksi W., Taylor B., Anderson P. Epidemiology and alcohol policy in Europe. Addiction 2011, 106(Suppl 1):11-19.
68. van Amsterdam J., van den Brink W. Reduced-risk drinking as a viable treatment goal in problematic alcohol use and alcohol dependence. J Psychopharmacol 2013, 27:987-997.
69. Yager J.D.M., Halmi K.A., Herzog D.B., Mitchell J.E., Powers P., Zerbe K.J. Practice Guideline for the treatment of patients with eating disorders, 3rd Edition. Am J Psy 2006, [Accès au site le 11/06/2014]. http://www.psychiatryonline.org/pdfaccess.ashx%3FResourceID=243187%26PDFSource=62006.